Literature DB >> 8187077

Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.

S P Dowell1, P O Wilson, N W Derias, D P Lane, P A Hall.   

Abstract

In the important cytopathological distinction between benign and malignant lesions, there is always a residue of suspicious cases which cannot be satisfactorily diagnosed. Overexpression of the p53 tumor suppressor gene product has been consistently correlated with p53 missense gene mutation and is associated with malignancy. Therefore, assessment of p53 expression may assist in the cytopathological diagnosis of malignancy. Immunohistological assessment of p53 expression has been performed on a prospective series of 1333 nongynecological cytological specimens in the setting of a teaching hospital group. Evaluation of p53 staining was performed without knowledge of cytological diagnosis. Resultant p53 expression data were correlated with cytological diagnosis and clinical information. Of the 999 assessable cases, 956 had a clear cytological diagnosis. In these, p53 overexpression occurred in 108 cases of which 86 were malignant lesions. Of the 848 p53-negative cases, 119 were in fact neoplasms. The false positives were predominantly (19 of 22) reactive mesothelial proliferations, and overexpression occurred in only a small proportion of cells. While the sensitivity of p53 overexpression is low (p53 overexpression only occurring in 41.9% of tumors), the overall specificity is 97%. In the 43 cytopathologically suspicious cases, 7 were p53 positive, all of which proved to be malignant. In this prospective unselected series, we have conclusively demonstrated a close correlation between overexpression of p53 protein and neoplasia. Furthermore, we have shown the possible utility of p53 immunostaining in cytopathology. While there are important technical caveats and some cytological specimens are suboptimal for immunostaining, the data indicate that assessment of p53 is a valuable adjunct to morphological assessment in the analysis of cytopathologically suspicious cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187077

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast.

Authors:  G P Howes; J Stephenson; S Humphreys
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

2.  p53 gene product expression in resected non-small cell carcinoma of the lung, with studies of concurrent cytological preparations and microwave antigen retrieval.

Authors:  S Binks; C A Clelland; J Ronan; J Bell
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 3.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

4.  p53 protein expression in malignant, pre-malignant and non-malignant lesions of the lip.

Authors:  N Crosthwaite; D Teale; C Franklin; G A Foster; B M Stringer
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

5.  Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.

Authors:  Gabriela A Balogh; Daniel Mailo; Hector Nardi; Maria Marta Corte; Esteban Vincent; Elena Barutta; Guillermo Lizarraga; Pablo Lizarraga; Hector Montero; Roberto Gentili
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

6.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 7.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

8.  Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Authors:  Jonine D Figueroa; Mary Beth Terry; Marilie D Gammon; Thomas L Vaughan; Harvey A Risch; Fang-Fang Zhang; David E Kleiner; William P Bennett; Christine L Howe; Robert Dubrow; Susan T Mayne; Joseph F Fraumeni; Wong-Ho Chow
Journal:  Cancer Causes Control       Date:  2008-11-07       Impact factor: 2.506

9.  TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

10.  p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Authors:  Sabine Heublein; Sabina K Page; Doris Mayr; Nina Ditsch; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.